SpringWorks Therapeutics reported a net loss of $15.3 million, or $0.37 per share, for the first quarter of 2020. The company's cash and cash equivalents were $311.1 million as of March 31, 2020. They also announced the issuance of a new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039 and signed a clinical collaboration with Allogene to evaluate Nirogacestat in combination with Allogeneic BCMA CAR T Cell Therapy.